Cerus and OneBlood Enter into Agreement for the Use of INTERCEPT Platelets and Plasma

By: via Benzinga
Cerus Corporation (NASDAQ: CERS) announced today that OneBlood, Inc. has signed a multi-year purchase agreement for the INTERCEPT Blood ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.